Unraveling the anti-colorectal cancer mechanisms of polysaccharide: a multi-omics investigation into gut microbiota-metabolism-immunity crosstalk.
1/5 보강
[BACKGROUND] This study aimed to systematically investigate the anti-colorectal cancer efficacy and the underlying mechanisms of polysaccharide with a focus on its role in modulating the gut microbio
APA
Jiang J, Zhang X, et al. (2026). Unraveling the anti-colorectal cancer mechanisms of polysaccharide: a multi-omics investigation into gut microbiota-metabolism-immunity crosstalk.. Frontiers in pharmacology, 17, 1749532. https://doi.org/10.3389/fphar.2026.1749532
MLA
Jiang J, et al.. "Unraveling the anti-colorectal cancer mechanisms of polysaccharide: a multi-omics investigation into gut microbiota-metabolism-immunity crosstalk.." Frontiers in pharmacology, vol. 17, 2026, pp. 1749532.
PMID
41815917 ↗
Abstract 한글 요약
[BACKGROUND] This study aimed to systematically investigate the anti-colorectal cancer efficacy and the underlying mechanisms of polysaccharide with a focus on its role in modulating the gut microbiota-metabolism-immune axis.
[METHODS] A homogeneous ASP fraction was structurally characterized using HPSEC, monosaccharide composition analysis, SEM, and FT-IR. Its anti-tumor activity was evaluated in a CT-26 tumor-bearing mouse model through histopathology, tumor inhibition rate, immune organ indices, and serum cytokine (IFN-γ, TNF-α, IL-2) assays. The potential mechanisms of action were elucidated by integrating 16S rDNA sequencing of gut microbiota, determination of short-chain fatty acids (SCFAs), untargeted serum metabolomics using UPLC-Q-TOF/MS, molecular docking studies, Western blot analysis of key signaling proteins, and validation through cell experiments.
[RESULTS] ASP demonstrated significant dose-dependent anti-tumor activity, with the medium dose showing the highest efficacy (50.84% inhibition). It induced tumor cell apoptosis, normalized tumor-associated immune organ hypertrophy, and rebalanced pro- and anti-tumor cytokines. Metabolomics identified 12 key biomarkers, revealing that ASP primarily reversed CRC-induced disruptions in glycerophospholipid and tryptophan metabolism. Concurrently, ASP restored gut microbiota diversity, suppressed pro-inflammatory genera, and promoted beneficial bacteria and some SCFAs. Integrated correlation analysis established a robust link between microbiota remodeling and metabolic correction. Molecular docking, Western blot validation and cell experiments confirmed that ASP and its regulated metabolites could inhibit the activity of PLA2/TLR4/MyD88/NF-κB signaling pathway.
[CONCLUSION] The results indicate that anti-CRC effect of ASP may be jointly regulated through multiple pathways: correcting abnormal glycerophospholipid and tryptophan metabolism in the host, restoring the homeostasis of the intestinal microbiota, increase the content of some SCFAs, and inhibiting the TLR4/NF-κB signaling pathway.
[METHODS] A homogeneous ASP fraction was structurally characterized using HPSEC, monosaccharide composition analysis, SEM, and FT-IR. Its anti-tumor activity was evaluated in a CT-26 tumor-bearing mouse model through histopathology, tumor inhibition rate, immune organ indices, and serum cytokine (IFN-γ, TNF-α, IL-2) assays. The potential mechanisms of action were elucidated by integrating 16S rDNA sequencing of gut microbiota, determination of short-chain fatty acids (SCFAs), untargeted serum metabolomics using UPLC-Q-TOF/MS, molecular docking studies, Western blot analysis of key signaling proteins, and validation through cell experiments.
[RESULTS] ASP demonstrated significant dose-dependent anti-tumor activity, with the medium dose showing the highest efficacy (50.84% inhibition). It induced tumor cell apoptosis, normalized tumor-associated immune organ hypertrophy, and rebalanced pro- and anti-tumor cytokines. Metabolomics identified 12 key biomarkers, revealing that ASP primarily reversed CRC-induced disruptions in glycerophospholipid and tryptophan metabolism. Concurrently, ASP restored gut microbiota diversity, suppressed pro-inflammatory genera, and promoted beneficial bacteria and some SCFAs. Integrated correlation analysis established a robust link between microbiota remodeling and metabolic correction. Molecular docking, Western blot validation and cell experiments confirmed that ASP and its regulated metabolites could inhibit the activity of PLA2/TLR4/MyD88/NF-κB signaling pathway.
[CONCLUSION] The results indicate that anti-CRC effect of ASP may be jointly regulated through multiple pathways: correcting abnormal glycerophospholipid and tryptophan metabolism in the host, restoring the homeostasis of the intestinal microbiota, increase the content of some SCFAs, and inhibiting the TLR4/NF-κB signaling pathway.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Efficacy and Safety of Different Dosages of Anlotinib Combined with PD-1 Monoclonal Antibody in the Treatment of Advanced Non-Small Cell Lung Cancer.
- DNMT1 and DNMT3A drive hepatocellular carcinoma progression via epigenetic regulation and are inhibited by 5-azacytidine.
- STC2 promotes colorectal cancer progression via c-Myc-mediated glycolysis and the PI3K/AKT/mTOR pathway.
- Recapitulating lung cancer metastasis : Advances in organoid models and challenges in clinical translation (Review).
- Efficacy and safety of triple or dual therapies for metastatic hormone-sensitive prostate cancer: a systematic review and Bayesian network meta-analysis.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Revisiting multi-region 16S sequencing in gastric cancer.
- Metabolomics-based and functional validation to explore the effect of the gut microbe-associated metabolite guanidinoacetic acid on rectal adenocarcinoma.
- Exploring the characteristics of gut microbiome changes in lung cancer patients and healthy controls.
- Bacterial taxa associated with lung cancer cases in Southeast Asians: a pilot case-control study.
- The oral bacterial microbiota change in oral squamous cell carcinoma: a systematic review and meta-analysis.
- Comprehensive 16s rRNA sequencing and metabolomics to investigate the effect of anticancer bioactive peptides combined with oxaliplatin on gastric cancer.